Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

AbbVie (NYSE:ABBV) said it expects to record an impairment charge of approximately $3.5B related to the drug emraclidine, ...

RingCentral (RNG) shares have gained nearly 19% over the past six months, driven by expanding AI initiatives, strong demand ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

A new biotech start-up – Ouro Medicines – launched today with $120 million in funding from a Series A and a plan to develop ...

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 2 includes Neo Performance Metals, Fannie Mae, ...

AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ('Aspira' or the 'Company') (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of ...

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...

WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms.

Germany's biologics market, the largest in Europe, is expected to grow at a 3.8% CAGR from 2025 to 2035. AI is driving this growth by enhancing R&D, optimizing drug design, and identifying novel ...

Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...